Trisomy 21
0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Genome & CompanyKorea - Suwon
1 programIntegrated prenatal screening for Down's syndromeN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NateraPrenatal Screening for Down Syndrome With DNAFirst
Genome & CompanyIntegrated prenatal screening for Down's syndrome
UNION therapeuticscell-free fetal DNA
Clinical Trials (3)
Total enrollment: 5,919 patients across 3 trials
Prenatal Screening for Down Syndrome With DNAFirst
Start: Jun 2014Est. completion: Dec 2015100 patients
N/ACompleted
Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood
Start: Nov 2013Est. completion: Jun 20173,819 patients
N/ACompleted
Down Syndrome Screening Based on Dried Blood Spots and Cell-free Fetal DNA
Start: Apr 2013Est. completion: Jan 20152,000 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.